These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24270168)

  • 21. Introduction to special issue on viruses and microbes.
    Toussaint A; Prangishvili D; Molineux IJ
    Virology; 2012 Dec; 434(2):137. PubMed ID: 23217985
    [No Abstract]   [Full Text] [Related]  

  • 22. Kinetics of phage-mediated biocontrol of bacteria.
    Abedon ST
    Foodborne Pathog Dis; 2009 Sep; 6(7):807-15. PubMed ID: 19459758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophage biocontrol in animals and meat products.
    Atterbury RJ
    Microb Biotechnol; 2009 Nov; 2(6):601-12. PubMed ID: 21255295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural solution to antibiotic resistance: bacteriophages 'The Living Drugs'.
    Jassim SA; Limoges RG
    World J Microbiol Biotechnol; 2014 Aug; 30(8):2153-70. PubMed ID: 24781265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical aspects of phage therapy.
    Międzybrodzki R; Borysowski J; Weber-Dąbrowska B; Fortuna W; Letkiewicz S; Szufnarowski K; Pawełczyk Z; Rogóż P; Kłak M; Wojtasik E; Górski A
    Adv Virus Res; 2012; 83():73-121. PubMed ID: 22748809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The potential use of bacteriophages in view of the current antibiotic therapy crisis].
    Borysowski J; Weber-Dabrowska B; Górski A
    Pol Arch Med Wewn; 2005 Jan; 113(1):73-8. PubMed ID: 16130605
    [No Abstract]   [Full Text] [Related]  

  • 27. A bacteriophage journey at the European Medicines Agency.
    Debarbieux L; Pirnay JP; Verbeken G; De Vos D; Merabishvili M; Huys I; Patey O; Schoonjans D; Vaneechoutte M; Zizi M; Rohde C
    FEMS Microbiol Lett; 2016 Jan; 363(2):fnv225. PubMed ID: 26656541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational models of populations of bacteria and lytic phage.
    Krysiak-Baltyn K; Martin GJ; Stickland AD; Scales PJ; Gras SL
    Crit Rev Microbiol; 2016 Nov; 42(6):942-68. PubMed ID: 26828960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respirable bacteriophages for the treatment of bacterial lung infections.
    Hoe S; Semler DD; Goudie AD; Lynch KH; Matinkhoo S; Finlay WH; Dennis JJ; Vehring R
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):317-35. PubMed ID: 23597003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteriophages as twenty-first century antibacterial tools for food and medicine.
    Maura D; Debarbieux L
    Appl Microbiol Biotechnol; 2011 May; 90(3):851-9. PubMed ID: 21491205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience of the Eliava Institute in bacteriophage therapy.
    Kutateladze M
    Virol Sin; 2015 Feb; 30(1):80-1. PubMed ID: 25662889
    [No Abstract]   [Full Text] [Related]  

  • 32. Bacteriophages as an alternative strategy for fighting biofilm development.
    Parasion S; Kwiatek M; Gryko R; Mizak L; Malm A
    Pol J Microbiol; 2014; 63(2):137-45. PubMed ID: 25115107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteriophages, revitalized after 100 years in the shadow of antibiotics.
    Wei H
    Virol Sin; 2015 Feb; 30(1):1-2. PubMed ID: 25680442
    [No Abstract]   [Full Text] [Related]  

  • 34. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
    J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting phage therapy: new applications for old resources.
    Nobrega FL; Costa AR; Kluskens LD; Azeredo J
    Trends Microbiol; 2015 Apr; 23(4):185-91. PubMed ID: 25708933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bacteriophage therapy].
    Huovinen P
    Duodecim; 2003; 119(7):581-3. PubMed ID: 12762197
    [No Abstract]   [Full Text] [Related]  

  • 37. Phage Therapy Approaches to Reducing Pathogen Persistence and Transmission in Animal Production Environments: Opportunities and Challenges.
    Colavecchio A; Goodridge LD
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28664828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriophage therapy.
    Sulakvelidze A; Alavidze Z; Morris JG
    Antimicrob Agents Chemother; 2001 Mar; 45(3):649-59. PubMed ID: 11181338
    [No Abstract]   [Full Text] [Related]  

  • 39. Turning a new phage.
    Gravitz L
    Nat Med; 2012 Sep; 18(9):1318-20. PubMed ID: 22961150
    [No Abstract]   [Full Text] [Related]  

  • 40. Our Lasting Debts to Bacterial Viruses, with Another Perhaps on the Horizon.
    Pederson T
    FASEB J; 2019 Jan; 33(1):1-2. PubMed ID: 30593122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.